Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

35.59 -0.70 (-1.94%)
Streaming Delayed Price Updated: 10:34 AM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 936,412
Open 36.56
Bid (Size) 35.56 (2)
Ask (Size) 35.61 (2)
Prev. Close 36.29
Today's Range 34.66 - 36.56
52wk Range 15.81 - 41.06
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The strugglingh stock investor did a little bit of shopping on Tuesday, adding to some of her existing positions. 
Via The Motley Fool
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption
FDA approves Guardant Health's Shield blood test for colorectal cancer screening in adults 45+, marking the first FDA-approved blood test as a primary CRC screening option. Shield meets Medicare... 
Via Benzinga
Exposures Product Safety

Performance

YTD
+34.23%
+34.23%
1 Month
+25.92%
+25.92%
3 Month
+97.69%
+97.69%
6 Month
+59.86%
+59.86%
1 Year
-8.80%
-8.80%

More News

Read More
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
From Guardant Health, Inc.
Via Business Wire
Assessing Guardant Health: Insights From 7 Financial Analysts
Via Benzinga
Where Guardant Health Stands With Analysts
Via Benzinga
Evaluating Guardant Health: Insights From 5 Financial Analysts
Via Benzinga
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
From Guardant Health, Inc.
Via Business Wire
Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns
Via InvestorPlace
3 Precision Medicine Stocks Tailoring Treatments
Via InvestorPlace
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
Via Benzinga
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
3 Biotech Moonshots With Imminent Catalyst Potential
Via InvestorPlace
The 3 Best Personalized Medicine Stocks to Buy in July 2024
Via InvestorPlace
From ‘Sell’ to ‘Strong Buy’: 3 Dramatic Analyst U-Turns to Watch
Via InvestorPlace
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
From Guardant Health, Inc.
Via Business Wire
Guardant Health Named to TIME100 Most Influential Companies
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
Via Benzinga
Bull Market Blastoff: 3 Stocks Targeting 56% to 91% Returns
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
Via Benzinga
FDA Advisory Panel Supports Approval Of Guardant Health's Blood Test For Colorectal Cancer Screening
Via Benzinga
Exposures Product Safety
Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test
Via Investor's Business Daily
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.